Aim: To share the Tuscany single-centre experience about the employing of the novel therapeutic radiopharmaceutical 223Ra in the treatment planning of mCRPC pts.
Feasibility and efficacy of 223Ra-dichloride (223Ra) to treat bone metastases in patients (pts) with castration resistant prostate cancer (mCRPC)
BORSO', ELISA;BIASCO, ELISA;DEROSA, LISA;FALCONE, ALFREDO
2015-01-01
Abstract
Aim: To share the Tuscany single-centre experience about the employing of the novel therapeutic radiopharmaceutical 223Ra in the treatment planning of mCRPC pts.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Falcone_773422.pdf
accesso aperto
Tipologia:
Abstract
Licenza:
Creative commons
Dimensione
32.18 kB
Formato
Adobe PDF
|
32.18 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
